Monitoring treatment toxicities in patients with renal cell carcinoma

Drs Dan George and Tian Zhang from the Duke Prostate and Urologic Cancer Centre, Durham, USA, share their views on monitoring side effects to treatment of patients with renal cell carcinoma (RCC). Emphasis is placed on counselling patients on expectations and managing baseline co-morbidities. Maintaining a prescribed treatment schedule while focused on quality of life […]

read more

Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer

A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Immunotherapy combinations standard of care for advanced kidney cancer

In 2015, the standard treatment for most patients with advanced kidney cancer was a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) such as sunitinib or pazopanib for untreated patients, followed by a checkpoint inhibitor (PD-1 inhibitor) such as nivolumab for patients who fail treatment with a VEGF inhibitor. However, over the last several […]

read more

Individualised treatment plans improve outcomes for kidney cancer

Over the past couple of years there have been several approvals of new treatments and drug combinations for advanced/metastatic renal cell carcinoma (RCC) resulting in treatment plans that are tailored for the individual patient. Recent advances in the treatment of advanced/metastatic RCC include cabozantinib, nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib. Dr Ajjai Shivaram Alva, associate professor at […]

read more

PARP inhibitors, vaccines and combination therapies for kidney cancer

In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]

read more

Bone-targeted therapies may improve survival in metastatic kidney cancer patients

A recent study published in the journal Translational Oncology suggests that bone-targeted therapies, such as denosumab and zoledronic acid may have a continued role in the treatment of patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy and immunotherapy. Bone is the second most common site of metastasis in patients with […]

read more

Major updates in the management of metastatic kidney cancer

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, talks about the introduction of immunotherapy and immunotherapy-targeted therapy combinations over the past two years for the first-line treatment of metastatic renal cell carcinoma (RCC). Watch the video interview on Practice Update here

read more

Effectiveness of targeted therapy after immunotherapy in metastatic kidney cancer patients

In this retrospective international study, the effectiveness of targeted therapy following discontinuation of immunotherapy for patients with metastatic renal cell carcinoma (RCC) in the real world was investigated. There were 314 patients in the study; 276 (87.9%) were treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), such as sunitinib, axitinib and cabozantinib, […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more
Showing 1 to 10 of 111 results
  TOP